Article

Future directions in development of VEGF antagonists

Ranibizumab (Lucentis, Genentech) has revolutionized the treatment of age-related macular degeneration, but the impressive results from clinical trials lead to new questions. Is long-term suppression of vascular endothelial growth factor (VEGF) in the eye safe? Do other members of the VEGF gene family contribute to retinal vascular diseases? Are other cytokines or growth factors involved in disease pathogenesis? Are there safe and effective delivery methods other than monthly injections?

Ranibizumab (Lucentis, Genentech) has revolutionized the treatment of age-related macular degeneration, but the impressive results from clinical trials lead to new questions. Is long-term suppression of vascular endothelial growth factor (VEGF) in the eye safe? Do other members of the VEGF gene family contribute to retinal vascular diseases? Are other cytokines or growth factors involved in disease pathogenesis? Are there safe and effective delivery methods other than monthly injections?

Peter A. Campochiaro, MD, professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital School of Medicine, Baltimore, addressed these issues in a symposium on the use of VEGF inhibitors. He noted that results of a study in a transgenic mouse model in which VEGF signaling was blocked found that there was no effect on the vasculature or ERG function and no decrease in retinal ganglion cells or axons in the optic nerve over a 7-month period.

"Therefore, it appears that blockage of VEGF-A for long periods of time is safe," Dr. Campochiaro said.

He also described a study suggesting that other VEGF family members besides VEGF-A play a role in retinal disease. Preclinical and clinical studies of a chimeric protein that binds VEGF-A and B and placental growth factor (VEGF Trap-Eye, Regeneron) show that it causes a substantial reduction in choroidal neovascularization (CNV).

Platelet-derived growth factor-B (PDGF-B) also is likely to be involved in development of retinal disease. According to Dr. Campochiaro, kinase inhibitors that block both VEGF and PDGF were highly effective in preclinical studies, using a synergistic effect to completely eliminate CNV. A prodrug for a kinase inhibitor was tested in a small clinical trial; it was administered topically b.i.d. for 30 days and substantially reduced thickening and subretinal fluid. It was a pigmented agent that produced colored deposits on the cornea in many patients, however, and the trial was stopped.

"It does provide proof of concept for topical delivery of kinase inhibitors," Dr. Campochiaro said.

"VEGF antagonists provide a benefit for [CNV] and other disease indications as well, such as retinal neovascularization and ischemia due to macular edema," he continued. "They're certainly here to stay and will be the baseline on which other things are added. Improvements are likely, and certainly it's very likely that the newer antagonists will have greater potency and less specificity. In addition, there will be new modes of delivery, including topical delivery and sustained delivery."

Dr. Campochiaro said that sustained delivery of proteins is difficult, but possible, and that studies of this technology are underway. Sustained delivery of small kinase inhibitors is very feasible and is likely to be achieved in the near future.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.